[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100297905":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":10,"locations":41,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Ginkgo Leaf Center for Rare Disorders","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgical treatment",null,"The subject was received transnasal butterfly surgery.",[13],"Procedure: Transnasal butterfly surgery",{"label":15,"type":10,"description":16,"interventionNames":17},"Drug therapy","The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.",[18],"Drug: sandostatin",{"label":20,"type":10,"description":21,"interventionNames":22},"Radiotherapeutics","he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.",[23],"Radiation: radiotherapy",[25,30,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"PROCEDURE","Transnasal butterfly surgery","The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.",[9],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","sandostatin","The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient",[15],[36],"Lanreotide",{"type":38,"name":39,"description":33,"armGroupLabels":40,"otherNames":10},"RADIATION","radiotherapy",[20],[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"China Acromegaly Organization","RECRUITING","Guangzhou","Guangdong","510000","China","CN",{"type":51,"coordinates":52},"Point",[53,54],113.25,23.11667,{"lat":54,"lon":53},[57,62],{"name":58,"role":59,"phone":60,"phoneExt":10,"email":61},"Zhiyong Chen, Doctor","CONTACT","+86 18662702387","xieshengrong81@126.com",{"name":63,"role":59,"phone":64,"phoneExt":10,"email":65},"Ron Xie, Master","+86 13813904039","147392524@qq.com",{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100297905","the-longitudinal-approach-to-acromegaly-a-pattern-of-treatment-and-comparative-effectiveness-research-100297905",false,"NCT03158090","The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research","Inclusion Criteria:\n\n1. Be able and willing to sign the informed consent form (ICF)\n2. Male, female, age 18-75 years old (including 18 years old and 75 years old).\n3. Compliance with acromegaly diagnostic criteria:\n\n   * At least one laboratory or medical record shows that the patient is random GH ≥ 2.5 μg \u002F L\n   * At least one checklist or medical record shows radiographic evidence that the patient has a pituitary tumor\n\nExclusion Criteria:\n\n1. Ectopic secretion of GH or pituitary cancer\n2. The patient is diagnosed with other complicated malignancies, or has previously been diagnosed with another malignancy, and there is currently evidence of lesion residue.\n3. Have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study.\n4. Be a patient who, in the judgement of the Investigator, would be inappropriate for enrollment in this study","ALL","18 Years","75 Years",{"count":78,"type":79},1965,"ESTIMATED","OBSERVATIONAL","This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.",[83],"Acromegaly",[83],"2022-03-14",{"date":87,"type":88},"2022-03-16","ACTUAL",{"date":90,"type":88},"2017-12-15",{"date":92,"type":79},"2051-01-30",{"name":5,"class":6},1]